
Opinion|Videos|April 25, 2025
Preserving Beta Cell Function in T1D: Current Strategies and Emerging Therapies
A panelist discusses how preserving beta-cell function in type 1 diabetes (T1D) requires a multifaceted approach combining timely diagnosis, immunomodulatory therapies, optimal glycemic control and emerging technologies that can slow disease progression and improve patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What current strategies or therapies are being utilized to preserve beta cell function in patients with T1D?
- What pharmacologic and nonpharmacologic strategies are recommended by the American Diabetes Association to prevent the progression of early-stage T1D to clinical-stage 3 T1D?
- What are the most common challenges health care providers face when managing patients’ T1D?
- What opportunities are available for overcoming these challenges?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























